February 2026 in “International Journal of Molecular Sciences” In this study, researchers identified 47 proteins associated with male pattern baldness severity and prioritized five candidate genes, including druggable CD38, suggesting new non-hormonal targets for therapeutic development.
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that Arabidopsis thaliana mutants with altered AtRBOHC/RHD2 enzyme function showed abnormal protein regulation linked to increased drought sensitivity due to disrupted plasma membrane protein balance and cytoskeleton changes, as revealed through proteomic analysis and advanced microscopy.
March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
3 citations
,
October 2023 in “Journal of Pain” In this exploratory study of trigeminal neuralgia patients undergoing microvascular decompression surgery, differential protein expression in plasma and cerebrospinal fluid was observed between responders and non-responders, suggesting potential biomarkers to predict surgical success and providing insights into the mechanisms of pain relief.
Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.
